LONDON - Virax Biolabs Group Limited , an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced a strategic collaboration.
India remains on alert following the emergence of the JN.1 COVID-19 subvariant, with 21 reported cases nationwide. The WHO labeled JN.1 a variant of interest, prompting heightened scrutiny. Despite 30+ spike protein mutations, health risks are deemed low. Medical experts stress vigilance for common symptoms and caution against panic. Although higher transmissibility is observed, JN.1 appears less severe. Health authorities advocate preventive measures and readiness as research on this evolving variant continues.
Virax Biolabs Group Limited announced a strategic collaboration with the University of Manchester and the Northern Care Alliance Foundation Trust, who have a track record in working together to.
Virax Biolabs Group (VRAX) Enters Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.